Nectar Lifescience Ltd
Nectar Lifescience Ltd Share Price Today: Live Updates & Key Insights
Get insights on Nectar Lifescience Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Nectar Lifescience Ltd Share Price Chart
Nectar Lifescience Ltd Fundamentals
Traded Volume: 9,72,964
Market Cap(Cr): 332
Avg Traded Price 14.65
1 Year return -56.83%
Upper Circuit 15.3
Lower Circuit 13.9
P/E TTM -1.00
P/B Ratio -16.00
Traded Value(Cr) 144.00
EPS TTM -16.119
Book value -16.119
Dividend 0.00%
Nectar Lifescience Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Nectar Lifescience Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Nectar Lifescience Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -5.79%
1M +12.12%
3M -1.86%
1Y -56.83%
YTD -64.35%
Nectar Lifescience Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Nectar Lifescience Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 4.23L
Day Before Yesterday 6.04L
1W Avg 7.77L
1M Avg 5.98L
3M Avg 3.67L
Nectar Lifescience Ltd Technical Details
Nectar Lifescience Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 14
Support 2 13
Support 3 13
Pivot Point : 15
Resistance 1 15
Resistance 2 16
Resistance 3 17
Nectar Lifescience Ltd Corporate Actions
Nectar Lifescience Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Nectar Lifescience Ltd’s capital allocation strategies.
All
Ex-Date 11-Sep-2020 Type D Description 0.05/share@5.00% Record Date - Ratio 5.00
Ex-Date 19-Sep-2019 Type D Description 0.05/share@5.00% Record Date - Ratio 5.00
Ex-Date 19-Sep-2018 Type D Description 0.05/share@5.00% Record Date - Ratio 5.00
Ex-Date 20-Sep-2017 Type D Description 0.05/share@5.00% Record Date - Ratio 5.00
Ex-Date 22-Sep-2016 Type D Description 0.10/share@10.00% Record Date - Ratio 10.00
Ex-Date 22-Sep-2015 Type D Description 0.10/share@10.00% Record Date - Ratio 10.00
Ex-Date 21-Aug-2014 Type D Description 0.10/share@10.00% Record Date - Ratio 10.00
Ex-Date 19-Sep-2013 Type D Description 0.10/share@10.00% Record Date - Ratio 10.00
Ex-Date 20-Sep-2012 Type D Description 0.10/share@10.00% Record Date - Ratio 10.00
Ex-Date 21-Sep-2011 Type D Description 0.10/share@10.00% Record Date - Ratio 10.00
Ex-Date 21-Jan-2010 Type D Description 0.25/share@25.00% Record Date 22-Jan-2010 Ratio 25.00
Ex-Date 03-Sep-2009 Type D Description 0.10/share@10.00% Record Date - Ratio 10.00
Ex-Date 12-Nov-2008 Type S Description share@1:10.00 Record Date 20-Nov-2008 Ratio 1:10.00
Ex-Date 18-Sep-2008 Type D Description 4.00/share@40.00% Record Date - Ratio 40.00
Ex-Date 18-Sep-2007 Type D Description 2.00/share@20.00% Record Date - Ratio 20.00
Dividends
Announcement Date 11-Sep-2020 Ex Dividend Date 11-Sep-2020 Dividend(%) 5
Announcement Date 19-Sep-2019 Ex Dividend Date 19-Sep-2019 Dividend(%) 5
Announcement Date 19-Sep-2018 Ex Dividend Date 19-Sep-2018 Dividend(%) 5
Announcement Date 20-Sep-2017 Ex Dividend Date 20-Sep-2017 Dividend(%) 5
Announcement Date 22-Sep-2016 Ex Dividend Date 22-Sep-2016 Dividend(%) 10
Announcement Date 22-Sep-2015 Ex Dividend Date 22-Sep-2015 Dividend(%) 10
Announcement Date 21-Aug-2014 Ex Dividend Date 21-Aug-2014 Dividend(%) 10
Announcement Date 19-Sep-2013 Ex Dividend Date 19-Sep-2013 Dividend(%) 10
Announcement Date 20-Sep-2012 Ex Dividend Date 20-Sep-2012 Dividend(%) 10
Announcement Date 21-Sep-2011 Ex Dividend Date 21-Sep-2011 Dividend(%) 10
Announcement Date 21-Jan-2010 Ex Dividend Date 21-Jan-2010 Dividend(%) 25
Announcement Date 03-Sep-2009 Ex Dividend Date 03-Sep-2009 Dividend(%) 10
Announcement Date 18-Sep-2008 Ex Dividend Date 18-Sep-2008 Dividend(%) 40
Announcement Date 18-Sep-2007 Ex Dividend Date 18-Sep-2007 Dividend(%) 20
Bonus
No Bonus has been declared by NECLIFE
Splits
Record Date 20-Nov-2008 Split Date 12-Nov-2008 Face Value (Before/After) 10.00/1.00
Others
Rights No Rights has been declared by NECLIFE
Nectar Lifescience Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Nectar Lifescience Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Nectar Lifescience Ltd's relative performance and valuation against major competitors.
Nectar Lifescience Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Nectar Lifescience Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 169.44 Mar 2024 224.69 Mar 2023 133.37 Mar 2022 95.04 Mar 2021 21.33
PARTICULARS Investing Activities Mar 2025 -41.93 Mar 2024 -17.03 Mar 2023 52.03 Mar 2022 16.64 Mar 2021 -28.62
PARTICULARS Financing Activities Mar 2025 -128.09 Mar 2024 -205.43 Mar 2023 -185.57 Mar 2022 -119.38 Mar 2021 11.49
PARTICULARS Net Cash Flow Mar 2025 -0.58 Mar 2024 2.23 Mar 2023 -0.17 Mar 2022 -7.70 Mar 2021 4.20
Nectar Lifescience Ltd Shareholding Pattern
This shows the ownership breakdown of Nectar Lifescience Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 44.91%
Public 54.37%
Other Institutions 0.1%
FII 0.62%
Mutual Funds null%
About Nectar Lifescience Ltd
Nectar Lifescience Limited was initially incorporated on June 27, 1995 as 'Surya Medicare Limited'. On March 26, 2004, Company changed the name from 'Surya Medicare Limited' to 'Nectar Lifescience Limited'. NECLIFE is an integrated pharmaceutical organization, engaged in manufacturing and delivering high quality pharmaceutical products. It is a global pharmaceutical company specializing in Cephalosporins. Nectar excels in Cephalosporin APIs production with certified facilities meeting global standards. Nectar has two manufacturing units with 13 facilities. The Plant has a total oral and sterile capacity of more than 2000 MT. All its facilities can be converted to multi-purpose plants based on product basket requirement. Company is the world's leading producer of Cefixime Trihydrate, Cefuroxime Axetil, Cefpodoxime Proxetil and Sterile APIs. Company's business operations are primarily concentrated on manufacturing and marketing of oral and sterile cephalosporins, phytochemicals and allied products. They manufacture and sell a range of cephalosporins and phytochemicals. They are also engaged in contract manufacturing of API's for pharmaceutical players.The company was established pursuant to a financial collaboration agreement between the Promoters and Punjab State Industrial Development Corporation. In April 1997, the company commenced business with the commercial production of Oral Bulk Drugs at their manufacturing facility located in the B Category zone of Punjab. In March 1998, they started the production of Sterile Bulk Drugs. In the year 1999, they added the formulation facilities by setting up a vial filing section for Crystalline Sterile Bulk Drugs.In the year 2000, the company undertook an expansion by increasing the installed capacity Crystalline Sterile Bulk Drugs from 406 MT to 810 MT. In the year 2001, they also installed one Crystalline section of 65 MT per annum, which commenced production in October 2001. In the year 2002, the company undertook another expansion programme increasing the production capacity for Cephalosporin Sterile. In October 18, 2002, they incorporated Chempharma (Pvt) Ltd as a wholly-owned subsidiary company in Sri Lanka to manufacture API intermediaries.In the year 2003, the company commenced modernization / expansion plan for increasing our presence in the Cephalosporins segment. In April 2003, the company bought back the entire shareholding of PSIDC at a price of Rs 16.47 per share under the One Time Settlement policy announced by Government of Punjab - Industrial Policy, 2003. In the year 2004, the company started production in a portion of the new Cephalosporins plant. During the year 2006-07, the company commissioned a state-of-the-art facility dedicated to the non-antibiotic therapeutic segment in compliance with stringent US-FDA and EDQM guidelines. The company established a state-of-the-art mint derivatives plant, initiating its business activity into the phytochemicals arena. They also up a menthol flakes facilities at SIDCO Industrial Complex, Jammu to add to the requisite business activity with all the locational benefits to the industry in J&K. They commissioned a unit in Derabassi to process menthol into powder and crystal formsThe company also established an Empty Hard Gelatin Capsule unit at Baddi, Himachal Pradesh referred to as Unit VII which commenced production with effect from April 2007. In April 2008, they set up a state-of-the-art facility, Unit X at Derabassi, which commissioned on April 17, 2008.During the year 2008-09, the company increased the production capacity of Bulk Drug & Sterile from 425 MT to 650 MT. Also, they increased the production capacity of Phytochemicals - Menthol from 6000 MT to 7600 MT. They launched 30 formulation brands (P2P). Also, they established a fully-owned formulation R&D centre in Derabassi dedicated to non-cephalosporins related developments like oncology, anti-diabetes, cardiovascular system, female healthcare and anti-HIV.During the year 2009-10, the company increased the production capacity of Bulk Drug & Sterile from 650 MT to 1600 MT. Also, they launched the diagnostic division during the year. During FY 2010-11, M/s Nectar Capital Limited was incorporated in Mauritius and M/s Nectar Lifesciences UK Limited, was incorporated in United Kingdom. Nectar Lifesciences US, LLC in United States was also incorporated during year 2014-15, which commenced the business operations of trading in pharmeceutical products.In March 2011, the company received approval from the Japanese MOH for their product, Cefuroxime Axetil.Neclife PT, Unipessoal LDA Portugal was incorporated as a subsidiary of the Company effective on July 11, 2019 to takeover MA from Nectar Lifesciences UK Limited. Nectar launched two new innovative products in EHGC menthol capsules (Nexxicap MintyTM) and pearl capsules (Nexxicap PearlTM) in 2023.The Company made sterile injectable capacity fully operational in FY 2025. The Active Pharmaceutical Ingredients (API) and Formulation Business of the Company was sold to Ceph Lifesciences Private Limited in 2025.
Chairman & Managing Director
Sanjiv Goyal
Registered office Village Saidpura, Tehsil Derabassi S A S Nagar, Mohali, Punjab, 140507
FAX :91-1762-308000
Background
Incorporation Year 1995
Face Value ₹1.00
Market Lot 1
FAQs on Nectar Lifescience Ltd
How to buy Nectar Lifescience Ltd shares on NSE?
To buy Nectar Lifescience Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Nectar Lifescience Ltd share price today?
The Nectar Lifescience Ltd share price on NSE is ₹14.80 today.
What is the market cap of Nectar Lifescience Ltd on NSE?
The company has a market capitalization of ₹331.91.
What is the PE & PB ratio of Nectar Lifescience Ltd?
PE is -1 and PB is -16.
What is the 52 Week High and Low of Nectar Lifescience Ltd shares?
Nectar Lifescience Ltd stock price high: ₹44.41 Nectar Lifescience Ltd stock price low: ₹13.05.